GLP-1s Could Change More Than Your Appetite: What We Know About Their Impact on ADHD, Brain Health and Libido - Marie Claire UK

TomAlright, I saw this and had to bring it to you: GLP-1s Could Change More Than Your Appetite: What We Know About Their Impact on ADHD, Brain Health and Libido. What's going through your head?

CarolThe libido piece is what actually worries me, because nobody talks about that side effect until it’s ruining people’s relationships. It’s easy to lose weight on these drugs, but hard to explain why you stopped wanting your partner at all. That gap between the marketing and the reality is where people get stuck.

TomYou’re putting a lot of weight on “nobody talks,” when most doctors are literally too busy to finish their own coffee. The real problem is that we treat appetite suppression as the whole job, ignoring that these drugs hit everything downstream, including how wired your brain feels day to day.

CarolBlaming doctor burnout misses the point entirely. The issue is that prescribing notes focus on BMI targets, leaving patients to discover the neurological and sexual fallout on their own. Until that data gets added to the chart, the burden stays squarely on the person taking the drug.

TomPutting it on the chart doesn’t solve anything if the prescriber has six minutes to review the whole file anyway. The real bottleneck isn’t missing paperwork, it’s that we haven’t figured out how to talk about arousal non-concordance without making everyone uncomfortable in the waiting room.

CarolWaiting-room discomfort isn’t the patient’s problem to manage. The real gap is that no one asks about desire discrepancy during follow-ups, so people assume they’re broken rather than medicated. That silence does more damage than any awkward five-minute chat ever could.

TomAssuming you're broken is exactly the wrong script, because the drug changes the baseline, not your character. But blaming the doctor for not asking ignores that half the time patients don't report libido drops themselves—they think it's normal aging or stress. So even with perfect follow-up questions, you miss it unless the patient knows it's a side effect worth mentioning.

CarolHalf the patients not reporting it proves nothing about follow-up quality, since they wouldn’t know to flag a side effect they’ve never been told exists. The fix is simple: list it on the consent form before the first dose, so the drop-off becomes a known variable instead of a mystery. Until that happens, we’re just guessing why people quit mid-treatment.

TomListing it on the consent form sounds good on paper, but people skim those things faster than they read a menu. A printed page won’t stick unless you actually say it out loud, and that takes time the system simply doesn’t give us.

CarolSkimming a menu doesn't mean people can't understand a spoken warning about their own body. The issue isn't whether the words land, it's whether anyone bothers to say them at all, especially regarding the ADHD symptoms some users start masking with medication. We need to stop assuming the system will deliver basic communication and hold individual practices accountable for skipping the basics.

TomHolding practices accountable for talking about masked ADHD symptoms is like punishing a shopkeeper for not explaining quantum physics. People on GLP-1s often feel less impulsive not because their condition vanished, but because their reward system got quieter. That shift needs context, not just blame, or nobody understands why their personality feels off.

CarolYou’re deflecting again. Saying “it’s complex” doesn’t excuse the fact that no one explains the reward-system shift before it starts. Patients deserve to know their impulsivity might change hands, not just guess why they suddenly can’t decide what to eat.

TomCalling it deflection misses that the biology here is genuinely strange—it’s not a switch flip, it’s a volume knob turning down on every signal at once. Telling someone their brain chemistry shifts when they lose weight is useful, but telling them how to interpret that quietness is where actual education starts. Blame gets headlines; understanding keeps people taking the meds correctly.

CarolUnderstanding the volume knob matters less if the person stops noticing their own signals entirely. For someone managing ADHD alongside weight loss, that sudden quietness can look like compliance when it’s actually a warning sign that their coping strategies are failing. We need clear guidance on distinguishing between improved focus and emotional numbness before patients misread their own state.

TomDistinguishing numbness from focus is a real clinical gap, not something a pamphlet solves. You want that distinction made explicit in follow-up visits, which means training providers to ask specifically about emotional texture, not just symptom checklists. Without that shift in how care is delivered, everyone stays stuck interpreting their own silence.

CarolTraining providers to probe emotional texture is necessary, but it fails without a standardized baseline to measure against. For patients on GLP-1s juggling ADHD, the goal isn't vague empathy; it's clearly defining what healthy somatic awareness looks like versus dangerous dissociation. Once that definition exists, accountability stops being abstract and becomes actionable.

TomDefining a baseline for somatic awareness is easier to say than to build, since we don't even agree yet if reduced libido is a side effect or a symptom of the reward dampening. Until we settle whether that drop is mechanical or psychological, any "standard" you propose is just guessing where the line should be.